Feb 13 (Reuters) - Allogene Therapeutics Inc ALLO.O:
ALLOGENE THERAPEUTICS ANNOUNCES PUBLICATION OF DURABLE RESPONSE DATA FROM PHASE 1 ALPHA/ALPHA2 TRIALS OF THE ALLOGENEIC CAR T CEMACABTAGENE ANSEGEDLEUCEL/ALLO-501 IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN THE JOURNAL OF CLINICAL ONCOLOGY
ALLOGENE THERAPEUTICS INC - CEMA-CEL ACHIEVES ORR OF 58% AND CR OF 42% IN STUDY
Source text: ID:nGNX75ZxGV
Further company coverage: ALLO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.